Objectives: The aim of the study was to compare the efficacy and tolerability of switching antiretroviraltherapy to dolutegravir+emtricitabine/tenofovir disoproxil fumarate (TDF) with those of switchingto elvitegravir/cobicistat/emtricitabine/TDF in clinical practice.MethodsIn a multicentre real-life observational study, we analysed data for HIV-infected patients onantiretroviral treatment with viral load<50 HIV-1 RNA copies/mL switching to dolutegravir+emtricitabine/TDF (dolutegravir group) or elvitegravir/cobicistat/emtricitabine/TDF (elvitegravirgroup). Follow-up was censored at 48 weeks.Results: The 48-week estimated proportion maintaining virological efficacy was 96.1% with dolutegravir(n=123) and 95.4% with elvitegravir (n=186;P=0.941). Patients in the dolutegravir groupshowed more treatment discontinuations, but these were mainly as a result of simplification. Theelvitegravir group showed more discontinuations because of renal adverse events (2.7% versus 0%with dolutegravir). Interestingly, no difference was observed between the two regimens in centralnervous system toxicity-related discontinuations. Switching to dolutegravir was associated with abetter blood lipid profile. Conclusions: Switching to dolutegravir+emtricitabine/TDF was associated with similar efficacy and tolerabilityto switching to elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed patients inclinical practice, although reasons for discontinuation showed differences between regimens. Theseresults should be interpreted with caution, as this is a nonrandomized comparison.

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study / G. Baldin, A. Ciccullo, A. Capetti, S. Rusconi, G. Sterrantino, M. Cossu, A. Giacomelli, F. Lagi, A. Latini, P. Bagella, A. De Luca, S. Di Giambenedetto, G. Madeddu. - In: HIV MEDICINE. - ISSN 1464-2662. - 20:2(2019 Feb), pp. 164-168. [10.1111/hiv.12688]

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study

A. Capetti;S. Rusconi;A. Giacomelli;
2019-02

Abstract

Objectives: The aim of the study was to compare the efficacy and tolerability of switching antiretroviraltherapy to dolutegravir+emtricitabine/tenofovir disoproxil fumarate (TDF) with those of switchingto elvitegravir/cobicistat/emtricitabine/TDF in clinical practice.MethodsIn a multicentre real-life observational study, we analysed data for HIV-infected patients onantiretroviral treatment with viral load<50 HIV-1 RNA copies/mL switching to dolutegravir+emtricitabine/TDF (dolutegravir group) or elvitegravir/cobicistat/emtricitabine/TDF (elvitegravirgroup). Follow-up was censored at 48 weeks.Results: The 48-week estimated proportion maintaining virological efficacy was 96.1% with dolutegravir(n=123) and 95.4% with elvitegravir (n=186;P=0.941). Patients in the dolutegravir groupshowed more treatment discontinuations, but these were mainly as a result of simplification. Theelvitegravir group showed more discontinuations because of renal adverse events (2.7% versus 0%with dolutegravir). Interestingly, no difference was observed between the two regimens in centralnervous system toxicity-related discontinuations. Switching to dolutegravir was associated with abetter blood lipid profile. Conclusions: Switching to dolutegravir+emtricitabine/TDF was associated with similar efficacy and tolerabilityto switching to elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed patients inclinical practice, although reasons for discontinuation showed differences between regimens. Theseresults should be interpreted with caution, as this is a nonrandomized comparison.
dolutegravir; efficacy; elvitegravir/cobicistat/tenofovir/emtricitabine; safety; tenofovir/emtricitabine
Settore MED/17 - Malattie Infettive
nov-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
Baldin_et_al-2019-HIV_Medicine.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 167.87 kB
Formato Adobe PDF
167.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/602382
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact